 It possesses broad antiviral activity against multiple protease inhibitor resistant HIV-1.Darunavir reached the market in 2006 and is a nonpeptidic analogue of amprenavir, with a critical change at the terminal tetrahydrofuran (THF) group.Instead of a single THF group, darunavir contains two THF groups fused in the compound, to form a bis-THF moiety which makes it more effective than amprenavir.